¼¼°èÀÇ ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð ¹× Á¡À¯À², ¿¹Ãø(2024-2032³â)
Fluidics for Preclinical Market, By Product, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1629204
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 284 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,612,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,598,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,017,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 41¾ï 2,043¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â¿¡ CAGR 6.33%·Î È®´ë

ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå ¿ªÇÐ

¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼ú ¹ßÀü, ½Å¾à °³¹ß, ºñ¿ë È¿À²¼º Çâ»óÀ¸·Î ½ÃÀå ¼ö¿ä ÃËÁø Àü¸Á

ÀüÀÓ»ó¿ë À¯Ã¼ ½ÃÀåÀº »ý¸í°øÇÐÀÇ ¹ßÀü°ú È¿À²ÀûÀÎ ½Å¾à°³¹ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ¸¶ÀÌÅ©·ÎÀ¯Ã¼°øÇÐÀÇ Çõ½ÅÀº ÀüÀÓ»ó ¿¬±¸¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ÷´Ü ·¦¿ÂĨ ½Ã½ºÅÛ ¹× Àå±â Ĩ Ç÷§ÆûÀÇ °³¹ßÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â À¯Ã¼ È帧À» Á¤¹ÐÇÏ°Ô Á¦¾îÇÏ°í »ý¸®Àû Á¶°ÇÀ» ¸ð¹æÇÒ ¼ö ÀÖÀ¸¹Ç·Î º¹ÀâÇÑ »ý¹°ÇÐÀû °úÁ¤À» ¿¬±¸ÇÏ´Â µ¥ ÇʼöÀûÀÎ ÅøÀÌ µÇ¾ú½À´Ï´Ù. Àΰ£°ú À¯»çÇÑ È¯°æÀ» ½Ã¹Ä·¹À̼ÇÇÒ ¼ö ÀÖ´Â ´É·ÂÀº ±âÁ¸ÀÇ 2Â÷¿ø ¼¼Æ÷¹è¾çÀ̳ª µ¿¹° ½ÇÇ躸´Ù ´õ Á¤È®ÇÑ ¸ðµ¨À» ¿¬±¸Àڵ鿡°Ô Á¦°øÇÕ´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷Àº ÀǾàǰ °³¹ß ½Ã°£°ú ºñ¿ëÀ» ÁÙ¿©¾ß ÇÑ´Ù´Â ¾Ð¹Ú¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Ç÷çÀ̵å¹Í½º ±â¹Ý ½Ã½ºÅÛÀº ³ôÀº 󸮷® ½ºÅ©¸®´× ±â´ÉÀ» Á¦°øÇÏ¿© ÅëÁ¦µÈ Á¶°Ç¿¡¼­ ¼öõ °³ÀÇ ¾à¹° Èĺ¸¹°ÁúÀ» ½Å¼ÓÇÏ°Ô Å×½ºÆ®ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. À̸¦ ÅëÇØ Ãʱ⠴ܰèÀÇ ¿¬±¸¸¦ °¡¼ÓÈ­Çϰí ÀÓ»ó °á°ú ¿¹ÃøÀ» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯Ã¼ ±â¹Ý ±â¼úÀº ±âÁ¸ ¹æ¹ý¿¡ ºñÇØ ÀûÀº ¾çÀÇ ½Ã·á, ÀûÀº ½Ã¾à, ÀûÀº ³ëµ¿·ÂÀ» ÇÊ¿ä·Î ÇϹǷΠºñ¿ë È¿À²¼ºÀÌ ³ô½À´Ï´Ù. ÀÌ´Â ¿¬±¸ ¿¹»êÀÌ ÇÑÁ¤µÈ Áß¼Ò±â¾÷(SME)À̳ª Çмú±â°ü¿¡ ƯÈ÷ À¯¸®ÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ È®À强Àº ½Å¾à °³¹ß¿¡¼­ ³ôÀº 󸮷® ¿ëµµ¸¦ Áö¿øÇÕ´Ï´Ù. Ç÷çÀ̵ñ½º¿Í AI, 3D ÇÁ¸°ÆÃ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ÅëÇÕÀº ±× Àû¿ë ¹üÀ§¸¦ ³ÐÇô°¡°í ÀÖ½À´Ï´Ù. Çаè, »ê¾÷°è, Á¤ºÎ °£ÀÇ Çù·ÂÀº Ç÷çÀ̵ñ½º¸¦ ±â¹ÝÀ¸·Î ÇÑ »õ·Î¿î ÀüÀÓ»ó ÅøÀÇ °³¹ßÀ» °¡¼ÓÈ­ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ ½ÃÀå : ÁÖ¿ä °í·Á»çÇ×

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 6.33%%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç°º°·Î º¸¸é AI ¹× ºòµ¥ÀÌÅÍ ºÐ¼® ºÐ¾ß¿¡¼­ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ÒÇÁÆ®¿þ¾î ¹× ¾×¼¼¼­¸® ºÎ¹®ÀÌ 2023³â¿¡ °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.

¿ëµµº°·Î´Â mRNA ¹é½Å, ¸é¿ªÃøÁ¤ ±â¼ú µî ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÀÓ»ó ºÎ¹®ÀÌ 2023³â ÁÖ¿ä ¿ëµµ°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é °¨¿°¼º ÁúȯÀÇ ³ôÀº À¯ÇàÀ¸·Î ÀÎÇØ º´¿ø ºÎ¹®ÀÌ 2023³â ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®ÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Áö¿ªº°·Î´Â ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ±¸ÃàµÈ ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÔ¿øÀ¸·Î ²ÅÇû½À´Ï´Ù.

ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

ÀüÀÓ»ó Ç÷çÀÌµå ¼¼°è ½ÃÀåÀº Á¦Ç°, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç°Àº Á¤¹Ð ÁÖ»ç±â ÆßÇÁ¿Í ¼ÒÇÁÆ®¿þ¾î ¹× ¾×¼¼¼­¸® µÎ °¡Áö·Î ³ª´¹´Ï´Ù. ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ŰƮÀÇ ±â¼ú ¹ßÀüÀÌ ÀÌ ºÎ¹® ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿ëµµº°·Î ÀÓ»ó, »ý¸í°úÇÐ ¿¬±¸, ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ¿¹Ãø ±â°£ Áß ÀÓ»ó ºÐ¾ß°¡ ¿ìÀ§¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ý¸í°úÇÐ ¿¬±¸ ºÐ¾ß´Â ½Å¾à ÀüÀÓ»ó ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚº°·Î º´¿ø, Ŭ¸®´Ð, ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ Áß ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÉÇ÷°ü, ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÇöÀå °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ ½ÃÀå : Áö¿ªº° ºÐ¼®

ÀüÀÓ»ó¿ë Ç÷çÀÌµå ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ºÏ¹Ì°¡ ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº ÁÖ·Î ¿¬±¸ ±â°ü ¹× Çмú ÇÁ·ÎÁ§Æ®¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ Â÷¿øÀÇ °­·ÂÇÑ ÀÚ±Ý Áö¿ø ´öºÐÀÔ´Ï´Ù. ¹Ì±¹Àº ¿¬°£ ÀÓ»ó½ÃÇè °Ç¼ö¿Í ½Å¾à ½ÂÀÎ °Ç¼ö¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â EUÀÇ REACH ±ÔÁ¦ µî µ¿¹°½ÇÇèÀ» Á¦ÇÑÇÏ´Â ¾ö°ÝÇÑ ¹ý·üÀÌ ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º µîÀÇ ±¹°¡¿¡¼­´Â ÇмúÀû, ¿¬±¸Àû ³ë·ÂÀÌ È°¹ßÇÏ°Ô ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ƯÈ÷ Áß±¹°ú Àεµ¿¡¼­ »ý¸í°úÇÐ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ÅõÀÚ°¡ Áõ°¡Çϸ鼭 °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â Áö¿ªÀÔ´Ï´Ù.

ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : °æÀï ±¸µµ

ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, ¸¹Àº ±â¾÷ÀÌ Áõ°¡ÇÏ´Â ÀüÀÓ»ó ¿¬±¸ ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ±â¼ú Çõ½Å¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷Àº Àû±ØÀûÀ¸·Î Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­ÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. ÀüÀÓ»ó ¿¬±¸¿¡¼­ ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼ú ¹× Àå±â Ĩ ±â¼úÀÇ ¹ßÀüÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº À¯Ã¼ È帧À» Á¤È®ÇÏ°Ô Á¦¾îÇÏ°í »ý¸®Àû Á¶°ÇÀ» ¸ð¹æÇÏ¿© ÀüÀÓ»ó ¸ðµ¨ÀÇ Á¤È®¼ºÀ» Çâ»ó½Ã۸ç, Opentrons¿Í Emulate¿Í °°Àº ÁÖ¿ä ±â¾÷ÀÌ ±â¼ú ¹ßÀüÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ Á¦Ç°ÀÇ µµÀÔ°ú ½ÅÈï ½ÃÀå ÁøÃâÀÌ ÇâÈÄ ¼ö³â°£ »ó´çÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½ºÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå ±¸µµ

Á¦7Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : Á¦Ç°º°

Á¦8Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : ¿ëµµº°

Á¦9Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ÀüÀÓ»ó¿ë Ç÷çÀ̵ñ½º ¾÷°è

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Fluidics for Preclinical Market size was valued at USD 4,120.43 Million in 2023, expanding at a CAGR of 6.33% from 2024 to 2032.

Fluidics for preclinical applications involves the use of fluidic systems, such as microfluidic devices or engineered fluid flows, to study biological, chemical, or pharmaceutical processes in the early stages of medical research. These systems are highly relevant in preclinical research for testing new drugs, studying disease mechanisms, or exploring the behavior of cells and biomolecules in controlled environments.

Fluidics for Preclinical Market- Market Dynamics

Growing advancement in microfluidic technology, drug discoveries and cost-effectiveness benefits are expected to propel market demand

The fluidics for preclinical market is growing rapidly, driven by advancements in biotechnology, increasing demand for efficient drug discovery methods. Recent innovations in microfluidics have revolutionized preclinical research, enabling the development of sophisticated lab-on-a-chip systems and organ-on-chip platforms. These devices allow precise control over fluid flows and mimic physiological conditions, making them indispensable tools for studying complex biological processes. Their ability to simulate human-like environments provides researchers with more accurate models than traditional 2D cell cultures or animal testing. The pharmaceutical and biotechnology industries face mounting pressure to reduce the time and cost of drug development. Fluidics-based systems provide high-throughput screening capabilities, enabling rapid testing of thousands of drug candidates under controlled conditions. This accelerates early-stage research while improving the prediction of clinical outcomes.

Fluidics-based technologies are cost-effective compared to traditional methods, requiring smaller sample volumes, fewer reagents, and less labor. This is particularly advantageous for small and medium-sized enterprises (SMEs) and academic institutions that may have limited research budgets. Furthermore, the scalability of these systems supports high-throughput applications in drug discovery. The integration of fluidics with AI, 3D printing, and bioinformatics is expanding its applications. Collaborative efforts between academia, industry, and government are accelerating the development of novel fluidics-based preclinical tools, boosting market growth.

Fluidics for Preclinical Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.33% over the forecast period (2024-2032)

Based on Product segmentation, software & accessories segment was predicted to show maximum market share in the year 2023, owing to increasing adoption of software solutions in AI and big data analytics.

Based on Application segmentation, clinical segment was the leading application in 2023, due to rising demand for mRNA vaccines, immunoassay techniques, etc.

Based on End User segmentation, hospitals segment was the leading End User segment in 2023, due to high prevalence of infectious diseases.

On the basis of region, North America was the leading revenue generator in 2023, owing to presence of established healthcare infrastructure.

Fluidics for Preclinical Market- Segmentation Analysis:

The Global Fluidics for Preclinical Market is segmented on the basis of Product, Application, End User, and Region.

The market is divided into two categories based on Product: precision syringe pumps and software & accessories. The software & services segment dominates the market. The growing tech advancements in microfluidic kits are contributing to segment demand.

The market is divided into three categories based on the Application: clinical, life science research, and others. The clinical segment is expected to dominate over the forecast period. Life science research segment is estimated to grow at fastest rate owing to increasing investment in preclinical research for novel drugs.

The market is divided into three categories based on End User: hospitals, clinics, and others. The hospitals segment dominates the market and is expected to maintain its high dominance during the forecast period. The increasing prevalence of chronic disorders such as cardiovascular, diabetes and the demand for point of care testing.

Fluidics for Preclinical Market- Geographical Insights

Worldwide, the Fluidics for Preclinical market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the Fluidics for Preclinical market, primarily due to the strong government and private funding for research institutions and academic projects. The U.S. leads in the number of clinical trials and new drug approvals annually. In Europe, stringent laws restricting animal testing, such as the European Union's REACH regulations. Strong academic and research initiatives in countries like Germany, the UK, and France. Asia Pacific is the fastest growing region with the increasing government investments in life sciences research, particularly in China and India.

Fluidics for Preclinical Market- Competitive Landscape:

The Fluidics for Preclinical Market is highly competitive, with numerous players focusing on innovations to cater to the increasing demand in preclinical research. Key players are actively enhancing their product portfolios and expanding their market presence. Advancements in microfluidics and organ-on-chip technologies are pivotal in preclinical research. These innovations offer precise control over fluid flows and mimic physiological conditions, enhancing the accuracy of preclinical models. Companies like Opentrons and Emulate leading technological advancements. The introduction of innovative products and the expansion into emerging markets are expected to drive substantial growth in the coming years.

Recent Developments:

In 2024, Opentrons introduced the Flex Prep, a no-code robot offering simplicity akin to a pipette with the versatility of a liquid handler.

In 2023, Opentrons launched the Flex lab robot, designed to democratize lab automation with an open-source API, facilitating integration with AI tools.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FLUIDICS FOR PRECLINICAL MARKET KEY PLAYERS

GLOBAL FLUIDICS FOR PRECLINICAL MARKET, BY PRODUCT- MARKET ANALYSIS, 2019-2032

GLOBAL FLUIDICS FOR PRECLINICAL MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

GLOBAL FLUIDICS FOR PRECLINICAL MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

GLOBAL FLUIDICS FOR PRECLINICAL MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Fluidics for Preclinical Market Overview

2. Executive Summary

3. Fluidics for Preclinical Key Market Trends

4. Fluidics for Preclinical Industry Study

5. Fluidics for Preclinical Market: COVID-19 Impact Analysis

6. Fluidics for Preclinical Market Landscape

7. Fluidics for Preclinical Market - By Product

8. Fluidics for Preclinical Market - By Application

9. Fluidics for Preclinical Market - By End User

10. Fluidics for Preclinical Market- By Geography

11. Key Vendor Analysis- Fluidics for Preclinical Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â